APOA5 Variant (Val153Met) Test

Your triglycerides, the main form of fat circulating in your blood, are shaped by what you eat and by genes you were born with. The APOA5 (apolipoprotein A-V) gene is one of the strongest single-gene influences on those triglyceride numbers, and small changes in its sequence can quietly raise lifetime risk for high triglycerides, atherogenic cholesterol patterns, and heart disease.

Val153Met is one such change. It swaps a single building block in the APOA5 protein, which can affect how well your body breaks down triglyceride-rich particles. Knowing whether you carry it gives you an early, fixed piece of information that helps explain stubborn triglyceride readings and shapes how aggressively you should manage diet, weight, and lipids over a lifetime.

What This Variant Actually Is

APOA5 is the gene that codes for apolipoprotein A-V, a protein made in the liver that helps enzymes pull triglycerides out of fat-carrying particles in your bloodstream. Variants in this gene are well-established determinants of plasma triglyceride concentration. People who carry pathogenic APOA5 changes tend to run higher triglycerides for life, and in severe cases the gene's failure can cause familial chylomicronemia syndrome, a rare condition with extreme triglyceride elevation and risk of pancreatitis.

Val153Met refers to a specific point change in the protein at position 153, where the building block valine is replaced by methionine. Most published research focuses on other APOA5 variants such as -1131T>C (rs662799), S19W, and rs2075291, and direct outcome data tied specifically to Val153Met is limited. The biology APOA5 controls is the same regardless of which variant you carry, but the size of the effect is variant-specific and not all APOA5 changes carry equal weight.

Triglyceride Levels

Across a large body of human genetic studies, variation in the APOA5 gene is independently linked to higher fasting triglycerides. In a study of 2,808 healthy men, APOA5 variation explained differences in triglyceride levels independent of nearby genes in the same cluster. Carriers of pathogenic APOA5 variants in clinical lipid registries can show highly variable triglyceride numbers over time, with secondary factors like weight, alcohol, and metabolic state amplifying the effect.

The takeaway for someone carrying an APOA5 variant: your triglyceride set point may sit higher than someone without the variant even when your diet looks identical, and your numbers may swing more in response to weight gain, refined carbohydrates, or alcohol. This is one of the few cardiometabolic test results that gives you a structural reason for stubborn triglyceride readings.

Heart Disease Risk

APOA5 variation has been linked to coronary artery disease in multiple large analyses. In a genetic and metabolomic study spanning 321,617 participants, lower triglycerides driven by APOA5 variation reduced coronary artery disease risk and shifted the lipoprotein profile in a more favorable direction, supporting apolipoprotein A-V as a causal node in heart disease. A collaborative analysis of 101 studies found that an APOA5 genetic variant supported a causal connection between triglyceride-mediated pathways and coronary heart disease.

In a study of 70,789 people, genetically elevated non-fasting triglycerides and remnant cholesterol driven partly by APOA5 variation acted as causal risk factors for myocardial infarction, not just markers riding alongside other risks. A meta-analysis of APOA5 polymorphisms across global populations found increased cardiovascular disease risk linked to the -1131T>C variant. The signal is strong for APOA5 as a gene, though the specific contribution of Val153Met to heart attack risk has not been quantified at the same level of detail.

Metabolic Syndrome and Diabetes

A meta-analysis found that APOA5 polymorphisms are associated with an increased prevalence of metabolic syndrome in adults. APOA5 variants have also been linked to lower adiponectin levels and higher arterial stiffness in 2,148 people with low HDL cholesterol, suggesting the variant's reach extends past triglycerides into broader metabolic dysfunction.

Diabetes risk specifically tied to APOA5 is less consistent. In the Northwick Park Heart Study II of 2,789 healthy men, APOA5 genotypes did not appear to alter the risk of developing type 2 diabetes. So while APOA5 variation tracks tightly with triglycerides and heart disease, it should not be read as a diabetes predictor on its own.

Familial Chylomicronemia Syndrome

Rare APOA5 variants can cause familial chylomicronemia syndrome (FCS), an inherited condition with extreme triglyceride levels and recurrent pancreatitis. A novel APOA5 mutation has been documented in patients with severe hypertriglyceridemia and low HDL who lacked mutations in other expected genes. Most APOA5 changes, including common variants, do not cause FCS, but they sit on the same biological pathway that, in its most severe form, produces the syndrome.

How to Read Your Result

This is a genetic test, so your result is reported as a genotype rather than a number on a scale. APOA5 variants are studied as fixed genetic risk factors and there are no major guidelines that define numeric thresholds, age-specific cutpoints, or sex-adjusted ranges for Val153Met. Carrier status is usually classified into three categories based on whether you inherited the variant from neither, one, or both parents.

What this means for you: clinical action depends less on the genotype label itself and more on what your actual triglyceride numbers, ApoB (apolipoprotein B), and family history are doing. Carriers with normal triglycerides on a healthy lifestyle may not need different treatment than non-carriers. Carriers whose triglycerides run high, who have a strong family history of early heart disease, or who develop pancreatitis episodes warrant a more aggressive workup.

Why One Reading Is the Whole Story

Genetic results do not change. You inherited your APOA5 sequence at conception and you will carry it for life. There is no benefit to retesting your genotype unless the original result is technically uncertain or you used a low-quality assay. What does need ongoing monitoring is the lipid pattern your genotype influences. Triglycerides, ApoB, and remnant cholesterol fluctuate with diet, weight, alcohol, and other variables, and they are the numbers you will track over time to see whether the genetic risk is translating into actual disease pressure.

A reasonable approach: confirm your genotype once, then build a regular lipid testing cadence around it. If you carry the variant, get a baseline lipid panel and ApoB now, retest in 3 to 6 months if you make lifestyle changes or start medication, and at least annually after that. Comparing year-over-year trends, ideally measured at the same lab, gives you a real read on whether your numbers are drifting up despite your best efforts or staying controlled.

When Results Can Be Misleading

Genetic results themselves are not subject to the day-to-day pre-analytical noise that plagues blood-based biomarkers. Your DNA does not change with fasting state, time of day, illness, or recent meals. The most common ways a genetic result misleads people are these:

• Variant-specific evidence gaps: most published outcome data on APOA5 comes from other variants like -1131T>C, S19W, and rs2075291, not Val153Met directly. A positive Val153Met result tells you that you carry a change in this gene, but the precise size of its effect on your triglycerides and heart disease risk has not been quantified as rigorously as for some other APOA5 variants.
• Confusion with single triglyceride readings: a normal fasting triglyceride number on the day you tested does not cancel out the genetic risk. Triglycerides swing widely with meals, alcohol, and weight changes. The variant tilts your long-term triglyceride trajectory, not your reading at any one moment.
• Assuming the variant explains everything: APOA5 is one of many genes that influence lipid metabolism. A carrier with high triglycerides may also have other genetic or lifestyle factors driving the number, and treatment should be guided by the lipid profile, not the genotype alone.
• Lab-to-lab assay differences: different genetic testing platforms cover different variants. Some panels report Val153Met explicitly, while others focus on more common APOA5 changes. If you have a result from one platform, that does not necessarily mean another platform would report the same set of variants.

What to Do With an Abnormal Result

If you carry the Val153Met variant, your next step depends on what your lipid numbers actually look like. Order or pull your most recent fasting triglycerides, ApoB, total cholesterol, HDL cholesterol, and LDL cholesterol. If your triglycerides are elevated (above 150 mg/dL fasting or above 175 mg/dL non-fasting) or your ApoB sits above optimal targets, that pattern combined with the variant is a stronger reason to act on diet, weight, alcohol, and medical therapy than either piece of information alone.

If your triglycerides are above 500 mg/dL or you have had pancreatitis, the workup should expand. A lipidologist can assess whether you have a more severe APOA5-related disorder, including familial chylomicronemia syndrome, and decide whether other genes (such as LPL, APOC2, GPIHBP1, and LMF1) need testing. Carriers with strong family histories of early heart attack should also have first-degree relatives consider lipid testing, since APOA5 variants travel through families.